Related Experiment Video
Updated: Aug 14, 2026

Murine Prostate Micro-dissection and Surgical Castration
Published on: May 11, 2016
[Dutasteride in the treatment of benign prostatic hyperplasia: an update]
1Department of Urology, The First Renmin Hospital of Lanzhou, Lanzhou, Gansu 730050, China.
Abstract:
Benign prostatic hyperplasia (BPH) is a common disease in older men. At present, 5alpha reductase inhibitor-based medication, preferred by most BPH patients as the first-choice therapy, is taking place of traditional transurethral resection of the prostate. This article presents an update of the researches on the treatment of BPH with dutasteride--a novel 5 alpha-reductase inhibitor.
Related Concept Videos
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Urinary Tract Infection III: Diagnostic Studies and Interprofessional Care
Urodynamic Studies: Uroflowmetry

